vs
Amalgamated Financial Corp.（AMAL）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Vericel Corp的季度营收约是Amalgamated Financial Corp.的1.1倍（$92.9M vs $85.2M），Vericel Corp同比增速更快（23.3% vs 9.4%），Amalgamated Financial Corp.自由现金流更多（$134.4M vs $12.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 4.3%）
CI金融集团是一家总部位于加拿大安大略省多伦多的投资管理公司，面向高净值个人投资者提供投资管理与财富管理服务，同时也为投资组合经理及机构投资者提供经纪与交易服务。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
AMAL vs VCEL — 直观对比
营收规模更大
VCEL
是对方的1.1倍
$85.2M
营收增速更快
VCEL
高出13.9%
9.4%
自由现金流更多
AMAL
多$121.6M
$12.8M
两年增速更快
VCEL
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $85.2M | $92.9M |
| 净利润 | — | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 39.0% | 24.1% |
| 净利率 | — | 25.0% |
| 营收同比 | 9.4% | 23.3% |
| 净利润同比 | — | 17.3% |
| 每股收益（稀释后） | $0.88 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMALVCEL
| Q4 25 | $85.2M | $92.9M | ||
| Q3 25 | $85.6M | $67.5M | ||
| Q2 25 | $80.9M | $63.2M | ||
| Q1 25 | $77.0M | $52.6M | ||
| Q4 24 | $77.9M | $75.4M | ||
| Q3 24 | $81.0M | $57.9M | ||
| Q2 24 | $78.5M | $52.7M | ||
| Q1 24 | $78.3M | $51.3M |
净利润AMALVCEL
| Q4 25 | — | $23.2M | ||
| Q3 25 | $26.8M | $5.1M | ||
| Q2 25 | $26.0M | $-553.0K | ||
| Q1 25 | $25.0M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $27.9M | $-901.0K | ||
| Q2 24 | $26.8M | $-4.7M | ||
| Q1 24 | $27.2M | $-3.9M |
毛利率AMALVCEL
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
营业利润率AMALVCEL
| Q4 25 | 39.0% | 24.1% | ||
| Q3 25 | 42.9% | 5.1% | ||
| Q2 25 | 43.8% | -3.2% | ||
| Q1 25 | 45.1% | -24.3% | ||
| Q4 24 | 42.4% | 24.5% | ||
| Q3 24 | 47.2% | -4.3% | ||
| Q2 24 | 45.6% | -11.5% | ||
| Q1 24 | 49.2% | -10.7% |
净利率AMALVCEL
| Q4 25 | — | 25.0% | ||
| Q3 25 | 31.3% | 7.5% | ||
| Q2 25 | 32.1% | -0.9% | ||
| Q1 25 | 32.5% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 34.5% | -1.6% | ||
| Q2 24 | 34.1% | -8.9% | ||
| Q1 24 | 34.8% | -7.5% |
每股收益（稀释后）AMALVCEL
| Q4 25 | $0.88 | $0.46 | ||
| Q3 25 | $0.88 | $0.10 | ||
| Q2 25 | $0.84 | $-0.01 | ||
| Q1 25 | $0.81 | $-0.23 | ||
| Q4 24 | $0.78 | $0.40 | ||
| Q3 24 | $0.90 | $-0.02 | ||
| Q2 24 | $0.87 | $-0.10 | ||
| Q1 24 | $0.89 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $291.2M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $794.5M | $354.6M |
| 总资产 | $8.9B | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMALVCEL
| Q4 25 | $291.2M | $137.5M | ||
| Q3 25 | $115.5M | $135.4M | ||
| Q2 25 | $171.1M | $116.9M | ||
| Q1 25 | $65.7M | $112.9M | ||
| Q4 24 | $60.7M | $116.2M | ||
| Q3 24 | $149.2M | $101.7M | ||
| Q2 24 | $58.0M | $102.5M | ||
| Q1 24 | $155.2M | $110.6M |
股东权益AMALVCEL
| Q4 25 | $794.5M | $354.6M | ||
| Q3 25 | $775.6M | $321.9M | ||
| Q2 25 | $754.0M | $306.8M | ||
| Q1 25 | $736.0M | $295.5M | ||
| Q4 24 | $707.7M | $292.0M | ||
| Q3 24 | $698.2M | $257.5M | ||
| Q2 24 | $646.0M | $243.0M | ||
| Q1 24 | $616.8M | $233.9M |
总资产AMALVCEL
| Q4 25 | $8.9B | $488.0M | ||
| Q3 25 | $8.7B | $453.3M | ||
| Q2 25 | $8.6B | $435.6M | ||
| Q1 25 | $8.3B | $424.6M | ||
| Q4 24 | $8.3B | $432.7M | ||
| Q3 24 | $8.4B | $390.4M | ||
| Q2 24 | $8.3B | $376.8M | ||
| Q1 24 | $8.1B | $356.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $135.8M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $134.4M | $12.8M |
| 自由现金流率自由现金流/营收 | 157.8% | 13.8% |
| 资本支出强度资本支出/营收 | 1.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | $229.4M | $24.7M |
8季度趋势，按日历期对齐
经营现金流AMALVCEL
| Q4 25 | $135.8M | $15.0M | ||
| Q3 25 | $39.5M | $22.1M | ||
| Q2 25 | $24.9M | $8.2M | ||
| Q1 25 | $34.2M | $6.6M | ||
| Q4 24 | $124.1M | $22.2M | ||
| Q3 24 | $35.8M | $10.2M | ||
| Q2 24 | $28.0M | $18.5M | ||
| Q1 24 | $31.3M | $7.2M |
自由现金流AMALVCEL
| Q4 25 | $134.4M | $12.8M | ||
| Q3 25 | $38.3M | $19.5M | ||
| Q2 25 | $24.2M | $81.0K | ||
| Q1 25 | $32.5M | $-7.6M | ||
| Q4 24 | $122.3M | $8.5M | ||
| Q3 24 | $35.2M | $-9.2M | ||
| Q2 24 | $27.8M | $1.8M | ||
| Q1 24 | $31.1M | $-6.8M |
自由现金流率AMALVCEL
| Q4 25 | 157.8% | 13.8% | ||
| Q3 25 | 44.7% | 28.8% | ||
| Q2 25 | 29.9% | 0.1% | ||
| Q1 25 | 42.2% | -14.5% | ||
| Q4 24 | 157.0% | 11.2% | ||
| Q3 24 | 43.4% | -15.9% | ||
| Q2 24 | 35.4% | 3.4% | ||
| Q1 24 | 39.7% | -13.3% |
资本支出强度AMALVCEL
| Q4 25 | 1.6% | 2.4% | ||
| Q3 25 | 1.4% | 3.9% | ||
| Q2 25 | 0.9% | 12.9% | ||
| Q1 25 | 2.3% | 27.0% | ||
| Q4 24 | 2.3% | 18.3% | ||
| Q3 24 | 0.7% | 33.5% | ||
| Q2 24 | 0.3% | 31.8% | ||
| Q1 24 | 0.3% | 27.3% |
现金转化率AMALVCEL
| Q4 25 | — | 0.65× | ||
| Q3 25 | 1.47× | 4.35× | ||
| Q2 25 | 0.96× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 1.28× | — | ||
| Q2 24 | 1.05× | — | ||
| Q1 24 | 1.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMAL
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
